Announced
Synopsis
Motilal Oswal and Invascent, two Indian financial services companies, acquired Symbiotec, a pharmaceutical company, from Actis. Financial terms were not disclosed. Mr. Vishal Tulsyan, ManagingDirector and CEO of MOPE commented, “Indianpharmaceutical companies continue to gain market share and credibilityworldwide. At MOPE, pharmaceuticals is one of our focus sectors and we continueto look for attractive investment opportunities therein. We are pleased to announceour investment in Symbiotec that presents a unique opportunity to partner withone of the largest vertically integrated company in the niche segment ofsteroids and hormones. Through this partnership, we intend to help Symbiotecachieve its vision of becoming an integrated “farm to pharmacy” company”.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.